<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Head Neck Pathol</journal-id><journal-id journal-id-type="iso-abbrev">Head Neck Pathol</journal-id><journal-title-group><journal-title>Head and Neck Pathology</journal-title></journal-title-group><issn pub-type="ppub">1936-055X</issn><issn pub-type="epub">1936-0568</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998733</article-id><article-id pub-id-type="pmc">PMC11861498</article-id>
<article-id pub-id-type="publisher-id">1766</article-id><article-id pub-id-type="doi">10.1007/s12105-025-01766-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Langerhans Cell Histiocytosis and Other Histiocytic Lesions</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>McKinney</surname><given-names>Reed A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Guanghua</given-names></name><address><email>Guanghua.wang.civ@health.mil</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Head and Neck Pathology, The Joint Pathology Center, Silver Spring, MD USA </aff><aff id="Aff2"><label>2</label>Molecular Diagnostics Laboratories, The Joint Pathology Center, Bethesda, MD USA </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>19</volume><issue>1</issue><elocation-id>26</elocation-id><history><date date-type="received"><day>17</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>8</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Histiocytoses, including Langerhans cell histiocytosis (LCH), comprise a diverse group of histiocytic disorders characterized by the abnormal accumulation and proliferation of histiocytes in various tissues or organs throughout the body, ranging from benign, self-limited conditions to aggressive malignancies and systemic inflammatory syndromes. These lesions present unique diagnostic challenges due to their broad spectrum of clinical presentations, overlapping histopathological and immunophenotypical features, and genetic complexity.</p></sec><sec><title>Methods</title><p id="Par2">This review analyzes major histiocytic lesions, focusing on their epidemiology, clinical presentations, histologic and immunophenotypic features, and genetic characteristics to facilitate accurate diagnosis and differentiation among these histiocytoses.</p></sec><sec><title>Results</title><p id="Par3">LCH, a well-recognized lesion, can affect various organ systems and necessitates differentiation from other types of histiocytoses such as Erdheim-Chester disease (ECD), Rosai-Dorfman-Destombes disease (RDD), and cutaneous and mucocutaneous non-Langerhans cell histiocytoses. Some histiocytic lesions, such as histiocytic sarcoma, are inherently malignant, while others, like hemophagocytic lymphohistiocytosis (HLH), manifest as severe, potentially life-threatening systemic inflammatory syndromes. Recent molecular genetic studies revealed recurrent genetic alterations in the MAPK pathway, such as <italic>BRAF</italic> V600E and <italic>MAP2K1</italic> in LCH and ECD, and <italic>KRAS</italic>, <italic>NRAS</italic>, and <italic>MAP2K1</italic> mutations in a subset of RDD. Malignant histiocytoses frequently show alterations in tumor suppressor genes like <italic>TP53</italic> and <italic>CDKN2A</italic>.</p></sec><sec><title>Conclusion</title><p id="Par4">Precise classification of histiocytic lesions relies on a comprehensive diagnostic approach that integrates clinical, histologic, immunophenotypic, and genetic data. Recent genetic advances shed light on these conditions&#x02019; unique but occasionally overlapping pathogenic mechanisms. Molecular genetics advancements continue to refine diagnostic accuracy and present new therapeutic targets, especially for aggressive or treatment-resistant cases.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Langerhans Cell Histiocytosis</kwd><kwd>Erdheim-Chester Disease</kwd><kwd>Rosai-Dorfman-Destombes Disease</kwd><kwd>Cutaneous and Mucocutaneous Non-Langerhans Cell Histiocytosis</kwd><kwd>Hemophagocytic Lymphohistiocytosis</kwd><kwd>Malignant Histiocytoses</kwd><kwd>ALK-positive Histiocytosis</kwd><kwd>Touton Giant Cells</kwd><kwd>Emperipolesis</kwd><kwd>Mitogen-activated Protein Kinase (MAPK)</kwd><kwd><italic>BRAF</italic></kwd><kwd><italic>MAP2K1</italic></kwd><kwd><italic>KRAS</italic></kwd><kwd><italic>NRAS</italic></kwd><kwd><italic>TP53</italic></kwd><kwd><italic>CDKN2A</italic></kwd></kwd-group><funding-group><award-group><funding-source><institution>Naval Medical Center San Diego</institution></funding-source></award-group><open-access><p>Open access funding provided by SCELC, Statewide California Electronic Library Consortium</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Langerhans cell histiocytosis (LCH) and other histiocytic lesions encompass a diverse set of lesions characterized by the accumulation of macrophage, dendritic cell, or monocyte-derived cells in various tissues and organs across all age groups. These lesions are frequently accompanied by an inflammatory infiltrate rich in eosinophils. In line with evolving new findings regarding the cellular origins, molecular pathology, and clinical features of histiocytic disorders, based on histology, phenotype, molecular alterations, and clinical and imaging characteristics, the Histiocyte Society in 2016 classified histiocytoses into five main disease groups: (1) Langerhans cell related, (2) cutaneous and mucocutaneous, (3) malignant histiocytoses, (4) Rosai-Dorfman- Destombes disease (RDD), and (5) hemophagocytic lymphohistiocytosis and macrophage activation syndrome. This classification reflects the clinical behavior of these diseases, ranging from benign, self-limited conditions to aggressive malignancies and systemic inflammatory syndromes [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par6">LCH, the most well-known of these disorders, is a clonal proliferation of Langerhans cells that can affect virtually any organ, most commonly the bones, skin, and lungs. The histopathologic hallmark of LCH is the presence of Langerhans cells with nuclear grooves and abundant eosinophilic cytoplasm, often accompanied by eosinophils, lymphocytes, and multinucleated giant cells. Immunohistochemically, LCH is defined by the expression of CD1a, S100, and langerin. Recent advances in genetic studies have shown that approximately 50&#x02013;60% of LCH cases harbor the <italic>BRAF</italic> V600E mutation, while about 25% of cases demonstrate somatic <italic>MAP2K1</italic> mutations [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Other histiocytic lesions, including Erdheim-Chester disease (ECD), Rosai-Dorfman-Destombes disease (RDD), cutaneous and mucocutaneous non-Langerhans cell histiocytoses, malignant histiocytoses (MH), hemophagocytic lymphohistiocytosis (HLH), and ALK-positive histiocytosis can show overlapping histological and clinical features, making differential diagnosis a significant challenge for pathologists. While these disorders share certain histopathological features, they exhibit distinct biological behaviors, ranging from benign self-limiting lesions to aggressive systemic diseases. The management and prognosis can vary widely depending on the underlying condition.</p><p id="Par7">This article aims to provide a comprehensive overview of LCH and other histiocytic lesions, focusing on their epidemiology, clinical presentations, histopathological, immunohistochemical, and molecular features, as well as the critical elements of differential diagnosis. The goal is to offer practical insights for pathologists, facilitating accurate classification for optimal clinical management of these often complex and challenging cases.</p></sec><sec id="Sec2"><title>Langerhans Cell Histiocytosis</title><p id="Par8">LCH is a clonal neoplastic proliferation of Langerhans cells expressing CD1a, langerin, and S100 protein and recurrent genetic alterations involving RAS/RAF/MEK/ERK pathway.</p><sec id="FPar1"><title>Epidemiology</title><p id="Par9">LCH remains a rare condition, with an estimated incidence of 2 to 10 cases per million children aged 15 years or younger. There is an approximal equal distribution in male and female patients [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Based on data from the Surveillance, Epidemiology, and End Results program for 2010 to 2016, the incidence of LCH was highest in the first year of life and then declined steadily with age. Beyond the age of 21, the rate of cases remains relatively stable across the adult age range [<xref ref-type="bibr" rid="CR6">6</xref>].</p></sec><sec id="FPar2"><title>Clinical Presentation</title><p id="Par10">Childhood LCH varies clinically, from mild, single-organ involvement to severe, multisystem disease with symptoms ranging from asymptomatic bone lesions to life-threatening systemic illness [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The skeleton is most affected, with up to 80% of cases presenting with bone lesions, which can appear radiographically as lytic (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A) or widespread [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par11">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Langerhans cell histiocytosis. (<bold>A</bold>) A skull radiograph shows the typical appearance of lytic lesions of Langerhans Cell Histiocytosis in bone. The lesion exhibits scalloped edges and sharp borders with a radiodense focus that is commonly seen in skull lesions. Image from Wang G. Langerhans Cell Histiocytosis, in DP: Molecular Oncology, 3e, by Vasef M, et al. Copyright Elsevier 2024. Reused with permission. (<bold>B</bold>) The H&#x00026;E section shows a sheet of oval-shaped Langerhans cells with eosinophilic cytoplasm, linear grooves, and inconspicuous nucleoli. Abundant eosinophils are present. (<bold>C</bold>) High-power view highlights the typical nuclear features of Langerhans cells. The nuclei are folded, show linear grooves, and often resemble coffee beans. (<bold>D</bold>) Immunostain CD1a diffusely marks Langerhans cells with positive membranous and cytoplasmic immunoreactivity. (<bold>E</bold>) Langerhans cells show a cytoplasmic granular staining pattern with langerin. (<bold>F</bold>) Langerhans cells show positive cytoplasmic and nuclear staining with S100</p></caption><graphic xlink:href="12105_2025_1766_Fig1_HTML" id="d33e302"/></fig>
</p><p>In adult LCH, most of the clinical and radiographic findings are like those of childhood LCH; however, isolated skin lesions are uncommon in adults. Radiographic bone lesions are present in 30&#x02013;50% of cases, frequently involving the skull and dental sites, and less frequently pelvis, vertebrae, ribs, and extremities with the characteristic &#x0201c;punched-out&#x0201d; bony lesions [<xref ref-type="bibr" rid="CR12">12</xref>]. Lung involvement in LCH can be part of multisystem disease or, more commonly in adults, can present as a primary or predominant form known as pulmonary LCH (PLCH). PLCH is a rare diffuse cystic lung disease, typically affecting young to middle-aged adults of both sexes and is seen almost exclusively in smokers or former smokers [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="FPar3"><title>Pathogenesis</title><p id="Par13">The etiology of LCH has been a subject of significant research, evolving from theories of reactive processes to its current classification as a clonal neoplastic disorder. Langerhans cells are specialized, bone marrow-derived dendritic cells that act as antigen-presenting cells in the epidermis and mucosal tissues. They are uniquely identified by the markers CD1a, S100, and langerin (CD207) and contain distinctive Birbeck granules (&#x0201c;tennis racket&#x0201d; structures). Research suggests that circulating CD1c&#x0207a; myeloid dendritic cells (mDCs) may serve as precursors to the pathogenic CD1a&#x0207a;CD207&#x0207a; cells in LCH and, once activated via the ERK pathway, migrate from the bloodstream to lesion sites [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>The neoplastic nature of LCH was first suggested by evidence of clonality in Langerhans cells through X-chromosome inactivation analysis. The presence of clonal histiocytes in all forms of LCH supports that it is a clonal neoplastic disorder rather than a reactive process with highly variable biological behavior [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p>The discovery of somatic mutations in the mitogen-activated protein kinase (MAPK) signaling pathway, especially <italic>BRAF</italic> V600E, has been key to understanding LCH pathogenesis. <italic>BRAF</italic> V600E, the most common mutation in LCH, occurs in 50&#x02013;60% of cases and leads to continuous MAPK pathway activation, driving uncontrolled Langerhans cell proliferation [<xref ref-type="bibr" rid="CR2">2</xref>]. In addition to <italic>BRAF</italic>, <italic>MAP2K1</italic> mutations are found in 20&#x02013;30% of LCH cases lacking <italic>BRAF</italic> mutations. Mutations in <italic>MAP2K1</italic>, which encodes the protein MEK1, lead to the constitutive activation of the pathway, promoting the uncontrolled proliferation of Langerhans cells&#x02014;a hallmark of LCH [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. <italic>MAP2K1</italic> and <italic>BRAF</italic> mutations are mutually exclusive. Mutually exclusive somatic activating mutations in MAPK pathway genes have now been identified in approximately 85% of LCH lesions [<xref ref-type="bibr" rid="CR18">18</xref>]. These mutations, more prevalent in aggressive forms of LCH, underscore the disease&#x02019;s neoplastic nature and serve as targets for therapy [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>While genetics is central to LCH pathogenesis, environmental and immune factors, such as viral infections (e.g., EBV) and exposures like tobacco smoke, are proposed contributors, though their precise roles remain unclear.</p><p>Immunological dysregulation significantly impacts LCH pathogenesis, with abnormal Langerhans cell proliferation accompanied by an inflammatory milieu of T cells, B cells, macrophages, and eosinophils, which suggests an immune response to the neoplastic cells. These immune cells, particularly T cells, secrete cytokines (e.g., IL-17, IL-6, and TNF-&#x003b1;) that contribute to the persistence of the lesions. The release of pro-inflammatory cytokines further promotes the abnormal proliferation of LCH cells and drives tissue destruction. Increased regulatory T cells (Tregs) and M2 macrophages in lesions further suppress the immune response, supporting LCH cell survival and lesion chronicity [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>Eosinophils are a significant inflammatory component in LCH lesions, but their recruitment mechanisms and functional role in the disease remain poorly understood. An early study suggests that eosinophil recruitment may be mediated by CCL5 produced by Langerhans cells, but this finding has yet to be widely validated [<xref ref-type="bibr" rid="CR20">20</xref>]. The precise contribution of eosinophils to LCH pathogenesis is not yet fully defined, underscoring the need for additional research to clarify their role in LCH.</p><p>Immune evasion is observed in LCH. Neoplastic LCH cells often express PD-L1, an immune checkpoint protein that interacts with PD-1 on T cells, leading to an inhibited immune response and allowing LCH cells to evade destruction [<xref ref-type="bibr" rid="CR21">21</xref>]. This immune-tolerant environment supports the persistence of LCH cells and contributes to the chronicity of the disease.</p></sec><sec id="FPar4"><title>Diagnosis</title><p id="Par20">Diagnosing LCH involves clinical assessment, histopathology, immunohistochemistry, molecular testing, and imaging to accurately identify the disease and assess its extent. A comprehensive evaluation of LCH has been outlined by Haupt et al. [<xref ref-type="bibr" rid="CR22">22</xref>] Definitive diagnosis is based on pathology, with diagnostic Langerhans cells showing ovoid shape, grooved nuclei, fine chromatin, and minimal nuclear atypia (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B-C); in some cases, the Langerhans cells have an increased Ki-67 proliferation index and mitotic activity. Along with Langerhans cells, a characteristic mixed inflammatory infiltrate is commonly seen, consisting of eosinophils, histiocytes, neutrophils, plasma cells, and small lymphocytes. Eosinophil-rich inflammatory infiltrates may also be seen in various conditions, such as allergic reactions, infections, and some malignancies. These add another layer of complexity to the diagnostic process and often require careful correlation with clinical, radiologic, and immunohistochemical findings to prevent misdiagnosis.</p><p>Langerhans cells stain positively for CD1a and langerin (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D-E) as well as S100, showing both cytoplasmic and nuclear staining patterns (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>F), while markers like CD1c, B-cell markers, T-cell markers, CD30, and CD23 are negative. The <italic>BRAF</italic> V600E mutation-specific antibody (VE1) is positive in many cases, along with vimentin, CD4, and CD68, while CD163 positivity is only observed in 5&#x02013;10% of cases. Immunohistochemistry for phosphorylated ERK (pERK) can also indicate MAPK pathway activity but is less specific than genetic testing [<xref ref-type="bibr" rid="CR21">21</xref>]. On electron microscopy, Birbeck granules may appear but are not essential for diagnosis.</p><p>Molecular testing has dramatically advanced diagnosing and treating LCH by identifying genetic mutations in the MAPK pathway. Approximately 50&#x02013;60% of LCH cases have the <italic>BRAF</italic> V600E mutation, which drives abnormal cell growth, while <italic>MAP2K1</italic> mutations are found in an additional 20&#x02013;30%, especially in <italic>BRAF</italic>-negative cases [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Next-generation sequencing (NGS), Sanger sequencing, and pyrosequencing are standard methods for detecting these mutations. Use of these molecular tests significantly enhances the accurate diagnosis of this entity.</p></sec><sec id="FPar41"><title>Treatment</title><p id="Par23">Recent international expert consensus recommendations outline treatment options for adult LCH that vary based on disease extent, organ involvement, and genetic profile [<xref ref-type="bibr" rid="CR12">12</xref>]. For patients with single-system LCH, surgery is often curative, with radiation as an alternative for inoperable lesions. Vinblastine and prednisone are standard first-line treatments for multisystem LCH, with more intensive chemotherapy reserved for high-risk organ involvement. Targeted therapies, including BRAF inhibitors (e.g., vemurafenib) for <italic>BRAF</italic> V600E mutations and MEK inhibitors (e.g., trametinib) for <italic>MAP2K1</italic> mutations, show promise in refractory cases [<xref ref-type="bibr" rid="CR21">21</xref>]. Supportive care, such as hormone replacement for pituitary involvement, is essential for quality of life.</p></sec><sec id="FPar5"><title>Prognosis</title><p id="Par24">The prognosis of LCH depends on disease extent, organ involvement, genetic mutations, and the responses to treatment. The prognosis in childhood LCH is guarded, as it is determined by the response to the initial therapeutic interventions, age of diagnosis, and extent of organ involvement. No response to initial therapy indicates a poor prognosis [<xref ref-type="bibr" rid="CR24">24</xref>]. Unifocal LCH has a 5-year overall survival rate of over 90%. Multisystem LCH involving high-risk organs like the liver, spleen, or bone marrow has a more guarded prognosis, requiring systemic therapies such as chemotherapy or targeted treatments. Outcomes vary based on treatment response and specific organ involvement, with adult prognosis often affected by treatment efficacy and relapse frequency. Prognosis can range from no sequelae to severe organ dysfunction (e.g., liver or lung) or neurodegeneration. The presence of <italic>BRAF</italic> V600E mutations, often seen in aggressive LCH, correlates with higher relapse rates and multisystem disease. Targeted therapies, including BRAF and MEK inhibitors, have improved outcomes in high-risk patients and those unresponsive to standard treatments [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec></sec><sec id="Sec4"><title>Erdheim-Chester Disease</title><p id="Par25">ECD is a clonal proliferation of histiocytes characterized by the infiltration of tissues by foamy histiocytes and Touton giant cells.</p><sec id="FPar6"><title>Epidemiology</title><p id="Par26">ECD is a rare, likely underdiagnosed condition, with an estimated 1,500 cases reported globally so far. Approximately 70% of cases occur in men, commonly diagnosed in adults between the ages of 40 and 60 years, with a mean age of 50 years. Cases in pediatric patients are rare, and they are frequently associated with LCH. Approximately 20% of ECD patients have an LCH lesion; it may also be seen in the same biopsy [<xref ref-type="bibr" rid="CR26">26</xref>].</p></sec><sec id="FPar7"><title>Clinical Presentation</title><p id="Par27">ECD is a systemic histiocytic neoplasm characterized by multiorgan proliferation of histiocytes in a fibrotic background. Bilateral symmetrical osteosclerosis of the long bones of the lower extremities is characteristic, occurring in up to 95% of cases [<xref ref-type="bibr" rid="CR27">27</xref>]. CD1a-negative histiocytes deposit in the bone, kidneys, retroperitoneum, heart, lungs, skin, and brain; however, the lymph nodes, spleen, and liver are generally spared [<xref ref-type="bibr" rid="CR28">28</xref>]. Lesional histiocytes can infiltrate retrobulbar soft tissue in the orbits, leading to exophthalmos and visual disturbances (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). Endocrine complications, such as diabetes insipidus, are common, alongside neurological symptoms like ataxia or cognitive changes, which occur in about 30&#x02013;50% of cases. Cardiovascular complications (e.g., pericardial infiltration and &#x0201c;coated aorta&#x0201d;) and retroperitoneal fibrosis (e.g., &#x0201c;hairy kidney&#x0201d; appearance) are also significant markers of ECD. Patients with ECD present with an autoimmune condition 41% of the time, commonly in the form of thyroiditis, Sj&#x000f6;gren syndrome, systemic lupus erythematous, pernicious anemia, or polymyalgia rheumatica [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par28">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Erdheim-Chester disease. (<bold>A</bold>) T1-weighted axial magnetic resonance image shows bilateral proptosis secondary to diffuse replacement of the intraconal fat by lesional tissue that encases the optic nerves marked with blue arrows. (<bold>B</bold>) Low-power view shows collections of foamy histiocytes with fibrosis. (<bold>C</bold>) High-power view highlights foamy histiocytes with abundant, lipid-rich cytoplasm and small nuclei. (<bold>D</bold>) Immunostain CD68 diffusely marks foamy histiocytes</p></caption><graphic xlink:href="12105_2025_1766_Fig2_HTML" id="d33e506"/></fig>
</p></sec><sec id="FPar8"><title>Pathogenesis</title><p id="Par29">The etiology is primarily linked to somatic mutations in genes in the MAPK pathway. The <italic>BRAF</italic> V600E mutation is the most common genetic alteration, occurring in approximately 50&#x02013;60% of patients with ECD. Other mutations affecting the MAPK pathway such as <italic>MAP2K1</italic> and <italic>ARAF</italic> have also been identified in ECD patients. These mutations lead to constitutive activation of the MAPK/ERK signaling pathway, resulting in uncontrolled cell proliferation and survival [<xref ref-type="bibr" rid="CR29">29</xref>]. In another study, 10.9% of patients presented with a <italic>PIK3CA</italic> mutation and 3.7% with an <italic>NRAS</italic> mutation [<xref ref-type="bibr" rid="CR30">30</xref>].</p></sec><sec id="FPar9"><title>Diagnosis</title><p id="Par30">The diagnosis of ECD involves clinical, radiological, histopathological, and genetic evaluations. Imaging, particularly PET-CT scans, plays a key role in diagnosis, showing symmetric long bone sclerosis, cardiovascular infiltration, or retroperitoneal fibrosis, which are characteristic findings in ECD [<xref ref-type="bibr" rid="CR31">31</xref>]. A biopsy is required for the definitive diagnosis of ECD. The hallmark of ECD is the presence of foamy histiocytes with abundant, lipid-rich cytoplasm and small nuclei. These histiocytic infiltrates are often surrounded by fibrosis and inflammatory infiltrates, including lymphocytes, plasma cells, and neutrophils, but eosinophils are rare to absent (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B-C). Multinucleated histiocytes or Touton giant cells are commonly encountered [<xref ref-type="bibr" rid="CR29">29</xref>]. Although not common, emperipolesis may also be present in ECD. Immunohistochemical analysis reveals that ECD histiocytes are typically positive for CD68, CD163, and factor XIIIa (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>D). Some histiocytes may be positive for S100 protein but negative for CD1a and langerin, which differentiates ECD from LCH [<xref ref-type="bibr" rid="CR32">32</xref>]. Testing for <italic>BRAF</italic> V600E and other MAPK pathway mutations (<italic>MAP2K1</italic> variants) is essential in ECD, as 50&#x02013;60% of patients have the <italic>BRAF</italic> V600E mutation. Testing for <italic>BRAF</italic> V600E and <italic>MAP2K1</italic> mutations is especially valuable in challenging cases where ECD may be confused with extracutaneous or disseminated juvenile xanthogranuloma because characteristic genetic aberrations favor the diagnosis of ECD.</p></sec><sec id="FPar10"><title>Treatment</title><p id="Par31">The treatment for ECD depends on the underlying genetic mutations and extent of disease, incorporating targeted therapies and supportive care. For patients with the <italic>BRAF</italic> V600E mutation, BRAF inhibitors (vemurafenib and dabrafenib) are effective with high response rates. In cases without <italic>BRAF</italic> mutations but with other MAPK pathway mutations (e.g., <italic>MAP2K1</italic>), MEK inhibitors (cobimetinib and trametinib) are alternatives. These inhibitors effectively target downstream MAPK elements, aiding in control, particularly for central nervous system involvement. In patients lacking targetable mutations or who cannot tolerate targeted therapies, interferon-alpha or cladribine can be used, though they are generally second-line options [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="FPar11"><title>Prognosis</title><p id="Par32">The prognosis of ECD largely depends on the sites of involvement, the extent of organ involvement, the presence of genetic alterations in the MAPK pathway, and the patient&#x02019;s response to treatment. ECD is a chronic, progressive disease; while many cases exhibit a slow progression, severe multisystem involvement&#x02014;particularly of the cardiovascular, central nervous, and renal systems&#x02014;can be life-threatening [<xref ref-type="bibr" rid="CR31">31</xref>]. The introduction of targeted therapies, especially BRAF and MEK inhibitors, has significantly improved survival outcomes, with high response rates and better disease control [<xref ref-type="bibr" rid="CR31">31</xref>]. For patients without actionable mutations, conventional therapies and supportive care remain essential, though the prognosis may be less favorable.</p></sec></sec><sec id="Sec5"><title>Cutaneous and Mucocutaneous Non-Langerhans Cell Histiocytoses</title><p id="Par33">Cutaneous and mucocutaneous histiocytoses refer to a diverse group of non-Langerhans cell (non-LCH) histiocytoses primarily affecting the skin and mucous membranes. These conditions range from benign, self-limited forms to more aggressive variants, with presentations including papules, nodules, or plaques. Common types include juvenile xanthogranuloma (JXG) and adult xanthogranuloma (AXG).</p><sec id="FPar12"><title>Epidemiology</title><p id="Par34">Cutaneous and mucocutaneous non-LCH histiocytoses include a wide variety of conditions affecting both children and adults. Precise incidence rates are unavailable for these disorders. Some subtypes, such as JXG, predominantly occur in children, whereas AXG and Necrotic Xanthogranuloma (NXG) are more commonly seen in adults [<xref ref-type="bibr" rid="CR1">1</xref>]. Overall, there is no significant sex predominance across these types.</p></sec><sec id="FPar13"><title>Clinical Presentation</title><p id="Par35">Cutaneous and mucocutaneous histiocytoses primarily affect the skin and mucous membranes, ranging from isolated benign lesions to more widespread forms, and are classified by site, age, and disease extent (solitary, localized, or disseminated). They fall under the &#x0201c;C&#x0201d; group of histiocytoses, including common lesions like juvenile and adult xanthogranulomas, and rarer forms such as solitary reticulohistiocytoma; benign cephalic histiocytosis; generalized eruptive histiocytosis; progressive nodular histiocytosis; cutaneous RDD and necrobiotic xanthogranuloma, two non-LCH histiocytoses with a major systemic involvement; xanthoma disseminatum; and multicentric reticulohistiocytosis [<xref ref-type="bibr" rid="CR1">1</xref>].</p></sec><sec id="FPar14"><title>Pathogenesis</title><p id="Par36">The etiology of cutaneous and mucocutaneous histiocytoses is unclear. While some histiocytoses, such as JXG, are thought to result from reactive immune processes rather than genetic causes, the exact triggers are not well understood. Limited evidence points to MAPK pathway mutations (e.g., <italic>BRAF</italic> and <italic>MAP2K1</italic>) in specific histiocytic disorders, though these are more commonly implicated in systemic rather than isolated cutaneous forms. The diversity within these conditions suggests a complex interplay of immune, environmental, and potentially genetic factors, and a definitive cause has not yet been established [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</p></sec><sec id="FPar52"><title>Diagnosis</title><p id="Par37">Diagnosing cutaneous and mucocutaneous histiocytoses involves clinical evaluation, histopathology, and immunohistochemistry to differentiate them from other histiocytic or dermatologic conditions. Histologically, JXG and AXG present as well-circumscribed nodules in the dermis, sparing the epidermis, and feature foamy cells, giant cells, and Touton giant cells, often accompanied by eosinophils, macrophages, and lymphocytes (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A-B). Over time, lesions typically undergo fibrosis. Solitary reticulohistiocytoma (SRH) also presents as a dermal nodule, resembling a xanthogranuloma composed of large histiocytes and multinucleated giant cells with abundant eosinophilic or ground-glass cytoplasm [<xref ref-type="bibr" rid="CR1">1</xref>]. Immunohistochemical staining confirms their histiocytic nature, with positive CD68, CD163, and factor XIIIa (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C-D) and negative CD1a, distinguishing JXG, AXG, and SRH from LCH. Other rarer cutaneous and mucocutaneous histiocytoses, such as benign cephalic histiocytosis, generalized eruptive histiocytosis, and xanthoma disseminatum, may show unique clinical and histological features, often with overlapping immunophenotypes including positive CD68, CD163, and factor XIIIa [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p>
<fig id="Fig3"><label>Fig. 3</label><caption><p>Juvenile xanthogranuloma. (<bold>A</bold>) Low-power view shows a proliferation of spindle cells in the dermis, sparing epidermis. (B) High-power shows more details of the proliferation of histiocytes arranged in short, interweaving fascicles that weave between collagen bundles. (<bold>C</bold>) Immunostain CD68 diffusely marks these histiocytes. (<bold>D</bold>) Immunostain factor XIIIa diffusely marks these histiocytes</p></caption><graphic xlink:href="12105_2025_1766_Fig3_HTML" id="d33e663"/></fig>
</p><p>In addition, given the appropriate clinical scenario, special stains (e.g., PAS-D and AFB) for microorganisms to exclude a dermal fungal or mycobacterial infection may be indicated.</p></sec><sec id="FPar15"><title>Treatment</title><p id="Par40">Treatment varies based on disease extent and severity. For patients with limited or isolated skin involvement, observation is often adequate, as many cases (e.g., JXG) resolve spontaneously. In symptomatic or cosmetically concerning cases, topical corticosteroids or surgical excision may be used [<xref ref-type="bibr" rid="CR34">34</xref>]. For extensive skin involvement or cases with systemic symptoms, systemic treatments are often necessary. Corticosteroids are the mainstay, particularly for reducing inflammation. Immunosuppressive agents like methotrexate or vinblastine are used in cases with significant spread or resistance to initial treatment [<xref ref-type="bibr" rid="CR33">33</xref>].</p></sec><sec id="FPar16"><title>Prognosis</title><p id="Par41">The prognosis of cutaneous and mucocutaneous histiocytoses varies by subtype and extent of disease involvement. Overall, prognosis is highly favorable for localized, self-limited forms but varies for more widespread or recurrent disease, depending on systemic involvement and treatment response [<xref ref-type="bibr" rid="CR33">33</xref>].</p></sec></sec><sec id="Sec6"><title>Rosai-Dorfman-Destombes Disease</title><p id="Par42">RDD is a histiocytic disorder characterized by the proliferation of large S100-positive histiocytes with conspicuous emperipolesis (lymphocytophagocytosis) of lymphocytes, plasma cells, or neutrophils.</p><sec id="FPar17"><title>Epidemiology</title><p id="Par43">RDD usually involves lymph nodes but also frequently involves extranodal sites. The cervical lymph nodes are the most commonly affected nodal site in RDD, typically presenting as bilateral, painless, massive cervical lymphadenopathy. Other nodal regions frequently involved include the mediastinal, inguinal, and retroperitoneal lymph nodes. Extranodal involvement is also a prominent feature of RDD, with commonly affected sites including the skin, nasal cavity, bones, soft tissues, retro-orbital tissues, gastrointestinal tract, kidneys and genitourinary tract, and respiratory system. It often affects young people (mean age, 30 years), and occurs more commonly in people of African descent, with a slight male predominance in this subset of affected individuals [<xref ref-type="bibr" rid="CR35">35</xref>].</p></sec><sec id="FPar53"><title>Clinical Presentation</title><p id="Par44">RDD is categorized primarily into three forms based on clinical presentation and associations [<xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par45">Sporadic RDD (non-cutaneous) is the most common form of all RDDs. It encompasses several subtypes, classified based on the site of involvement and their association with other conditions, including classic nodal RDD, extranodal RDD, neoplasia-associated RDD, and autoimmune disease-associated RDD. Additional details are provided in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p><p>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Classification of sporadic RDD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Subtype of Sporadic RDD</th><th align="left">Description</th><th align="left">Associated Conditions</th></tr></thead><tbody><tr><td align="left">Classic Nodal RDD</td><td align="left">Involves lymph nodes, primarily presenting as massive, painless cervical lymphadenopathy</td><td align="left">Lymphadenopathy</td></tr><tr><td align="left">Extranodal RDD</td><td align="left">Affects extranodal sites, including skin, bones, soft tissue, and retro-orbital tissues</td><td align="left">Skin lesions, bone involvement, soft tissue masses, retro-orbital abnormalities</td></tr><tr><td align="left">Neoplasia Associated RDD</td><td align="left">Occurs in conjunction with malignancies</td><td align="left">Lymphomas, leukemias, malignant histiocytosis</td></tr><tr><td align="left">Immune-Disease Associated RDD</td><td align="left">Linked to autoimmune conditions</td><td align="left">Lupus erythematous, idiopathic juvenile arthritis, autoimmune hemolytic anemia</td></tr></tbody></table></table-wrap>
</p><p>Familial RDD, linked to genetic syndromes, is rare and includes conditions such as H syndrome (Faisalabad Syndrome) and FAS deficiency-related RDD, also referred to as autoimmune lymphoproliferative syndrome-related RDD (ALPS-related RDD). H syndrome is caused by mutations in the <italic>SLC29A3</italic> gene and is characterized by nodal and extranodal RDD, along with features such as hyperpigmentation, short stature, and hypertrichosis. FAS deficiency-related RDD is a rare form of RDD that is associated with mutations in the <italic>TNFRSF6</italic> gene, which plays a critical role in regulating apoptosis. Patients with ALPS often present with systemic lymphoproliferation, autoimmune manifestations, and increased susceptibility to infections, reflecting broader immune dysregulation. FAS deficiency-related RDD is typically observed in more severe cases of ALPS patients.</p><p>Cutaneous RDD, classified separately under the &#x0201c;C group&#x0201d; of histiocytoses, predominantly affects the skin, presenting as papules or nodules, and is more frequent in older adults [<xref ref-type="bibr" rid="CR1">1</xref>]. Unlike nodal RDD, cutaneous RDD generally lacks systemic involvement and has a more favorable course&#x0200b; [<xref ref-type="bibr" rid="CR35">35</xref>].</p></sec><sec id="FPar18"><title>Pathogenesis</title><p id="Par49">The etiology of RDD remains partially understood and appears to involve both immune dysregulation and potential neoplastic processes. While RDD was previously considered a reactive disorder due to immune abnormalities and associations with autoimmune conditions, recent discoveries have identified somatic mutations in the MAPK pathway (<italic>KRAS</italic>, <italic>NRAS</italic>, <italic>MAP2K1</italic>, and <italic>ARAF</italic>) and activating mutations in <italic>CSF1R</italic> in some cases, suggesting a neoplastic origin in subsets of RDD [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. These mutations indicate a clonal process in certain cases, while others may arise from an immune-driven reaction to infectious or inflammatory triggers.</p></sec><sec id="FPar19"><title>Diagnosis</title><p id="Par50">The diagnosis of RDD requires a combination of clinical evaluation, histopathology, and immunohistochemistry. RDD often presents with massive, painless lymphadenopathy, particularly in the cervical lymph nodes, and may include extranodal manifestations in the skin, central nervous system, respiratory tract, and other sites. Radiologic imaging, particularly MRI and CT scans, helps assess the extent of extranodal disease, especially in cases with central nervous system or retroperitoneal involvement.</p><p>A tissue biopsy is essential for diagnosing RDD. Microscopically, RDD lesions are characterized by collections of histiocytes with large histiocytes displaying emperipolesis&#x02014;engulfment of intact lymphocytes, plasma cells, and neutrophils within the histiocyte cytoplasm (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A-B). Though nonspecific, this feature is a hallmark of RDD. A chronic inflammatory infiltrate with lymphocytes and plasma cells with rare or no eosinophils is commonly seen between collections of histiocytes. On low magnification, a striated appearance of the light and dark zones is appreciated. Immunohistochemically, RDD histiocytes are typically positive for S100, CD68, and CD163, but CD1a and langerin are negative, helping distinguish RDD from LCH and other histiocytic disorders (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C-D) [<xref ref-type="bibr" rid="CR35">35</xref>]. BCL1 positivity may aid in the diagnosis, particularly in extranodal presentations.</p><p>
<fig id="Fig4"><label>Fig. 4</label><caption><p>Rosai-Dorfman-Destombes disease. (<bold>A</bold>) Dense lymphohistiocytic infiltrate with plasma cells and areas of fibrosis. Scattered large histiocytic cells show significant emperipolesis. (<bold>B</bold>) Another case shows collections of histiocytes displaying emperipolesis. (<bold>C</bold>) Immunostain S100 is positive and outlines emperipolesis. (<bold>D</bold>) Immunostain CD163 is diffusely positive</p></caption><graphic xlink:href="12105_2025_1766_Fig4_HTML" id="d33e837"/></fig>
</p><p>Molecular testing for genetic alterations in the MAPK pathway is used to aid the diagnosis, and it is especially useful in refractory cases or when targeted therapy is considered. Approximately 50% of RDD lesions harbor mutations in genes in the MAPK/ERK pathway, including <italic>KRAS</italic>, <italic>NRAS</italic>, <italic>MAP2K1</italic>, <italic>ARAF</italic>, <italic>CSF1R</italic>, and rarely <italic>BRAF</italic> V600E [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p></sec><sec id="FPar20"><title>Treatment</title><p id="Par54">The RDD treatment is customized based on disease severity and extent. Mild, uncomplicated, or asymptomatic cases typically require observation and monitoring, while localized disease may benefit from surgical removal of affected lymph nodes or masses. Systemic therapies, including corticosteroids, sirolimus, chemotherapy, immunomodulatory therapy, targeted therapies, and radiotherapy, are considered for unresectable diseases [<xref ref-type="bibr" rid="CR36">36</xref>]. In 2022, the U.S. Food and Drug Administration (FDA) approved Cotellic (cobimetinib) for the treatment of adults with histiocytic neoplasms, including RDD [<xref ref-type="bibr" rid="CR38">38</xref>].</p></sec><sec id="FPar21"><title>Prognosis</title><p id="Par55">The prognosis of RDD varies based on disease extent and organ involvement. Most cases of classic nodal RDD are self-limited and have a favorable prognosis, often requiring minimal intervention. Extranodal or systemic forms, especially with central nervous system or respiratory involvement, may follow a more chronic and relapsing course, impacting quality of life and leading to potential complications [<xref ref-type="bibr" rid="CR36">36</xref>]. The development of targeted therapies for patients with RDD harboring MAPK pathway mutations has improved outcomes in refractory cases, offering more effective disease control.</p></sec></sec><sec id="Sec7"><title>Primary and Secondary Malignant Histiocytoses</title><p id="Par56">Malignant histiocytoses (MH) are a rare, aggressive group of malignant neoplasms originating from histiocytes or dendritic cells, characterized by the expression of histiocyte/dendritic cell markers such as CD68, CD163, CD4, and lysozyme [<xref ref-type="bibr" rid="CR1">1</xref>]. The diagnosis requires ruling out other tumors, confirmed by the absence of immunohistochemistry markers like keratins, EMA, Melan-A, HMB45, B and T lymphocyte markers, and follicular dendritic cell markers. These neoplasms are classified into primary and secondary forms [<xref ref-type="bibr" rid="CR1">1</xref>].</p><sec id="FPar22"><title>Epidemiology</title><p id="Par57">Both primary and secondary MH are extremely rare. Due to their rarity, epidemiological data are sparse, and diagnosis is usually confirmed in specialized medical centers with advanced diagnostics technologies.</p></sec><sec id="FPar23"><title>Clinical Presentation</title><p id="Par58">Primary MH include histiocytic sarcoma, Langerhans cell sarcoma, interdigitating dendritic cell sarcoma, and indeterminate dendritic cell tumor. They often involve lymph nodes and extranodal sites like the liver, spleen, and gastrointestinal tract and often present with nonspecific symptoms, such as fever, weight loss, fatigue, lymphadenopathy, and hepatosplenomegaly, with possible gastrointestinal, skin, or bone involvement causing localized symptoms.</p><p>Secondary malignant histiocytosis generally transforms from conditions like chronic lymphocytic leukemia, diffuse large B-cell lymphoma, or follicular lymphoma and presents similarly, with systemic symptoms and possible extranodal spread [<xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="FPar24"><title>Pathogenesis</title><p id="Par60">Primary MH are de novo malignancies arising from histiocytes or dendritic cells; there is no well-defined etiology, but MH are possibly linked to genetic mutations affecting cell differentiation and proliferation. Mutations in <italic>CDKN2A</italic>, <italic>BRAF</italic>, <italic>KRAS</italic>, <italic>NRAS</italic>, <italic>TP53</italic>, <italic>MAP2K1</italic>, <italic>NF1</italic>, <italic>PTPN11</italic>, and <italic>CSF1R</italic> have been identified in some primary MH lesions, contributing to unregulated cell growth [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. A study of genomic profiling of primary histiocytic sarcoma suggests the existence of a distinct subtype of primary histiocytic sarcoma characterized by <italic>NF1/PTPN11</italic> alterations with predilection for the gastrointestinal tract [<xref ref-type="bibr" rid="CR42">42</xref>]. The identification of pathogenic genetic mutations suggests a role in pathogenesis. However, the exact mechanisms and risk factors contributing to the development of primary malignant histiocytosis are poorly defined, warranting further research [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>Secondary MH results from anaplastic progression with aberrant expression of histiocyte/dendritic cell markers or transdifferentiation of an existing hematologic proliferation, particularly lymphomas and leukemias. These cases retain some molecular characteristics of the original malignancy, such as immunoglobulin gene rearrangements, the t(14;18) translocation, <italic>BRAF</italic> mutations, or other chromosomal alterations, distinguishing them from primary histiocytic neoplasms [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR43">43</xref>].</p></sec><sec id="FPar54"><title>Diagnosis</title><p id="Par62">As with the other histiocytic diseases, a combination of clinical, radiographic, and histologic phenotypes contributes to the diagnosis of a malignant process. Microscopically, MH is characterized by anaplastic histology consisting of histiocytic cells with large pleomorphic nuclei containing vesicular chromatin and distinct nucleoli, and abundant eosinophilic cytoplasm with significant mitotic activity with atypical mitoses (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A-B). These histopathological features are mandatory for diagnosis. Immunohistochemistry studies are needed to exclude other tumors in the differential diagnosis by showing negativity for keratins, EMA, Melan-A, HMB45, B and T lymphocyte markers, follicular dendritic cell (DC) markers, and expression of at least two of the following histiocyte/DC markers: CD68, CD163, CD4, and lysozyme (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>C) [<xref ref-type="bibr" rid="CR1">1</xref>]. A recent study by Ravindran et al. shows that all malignant histiocytic lesions express CD68 and BCL1 [<xref ref-type="bibr" rid="CR44">44</xref>]. MH can be categorized into four types of lineage differentiation: macrophages, monocytes, dendritic cells, and Langerhans cells [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p>
<fig id="Fig5"><label>Fig. 5</label><caption><p>Malignant histiocytosis. (<bold>A</bold>) Sheets of polygonal cells with abundant eosinophilic cytoplasm and pleomorphic nuclei with prominent nucleoli. (<bold>B</bold>) High-power view reveals an anaplastic appearance of malignant histiocytes with marked cytologic atypia. (<bold>C</bold>) Immunostain CD163 highlights malignant tumor cells. (<bold>D</bold>) CD1a is negative</p></caption><graphic xlink:href="12105_2025_1766_Fig5_HTML" id="d33e1009"/></fig>
</p><p>Given it overlapping features with MH, melanoma should be excluded using melanocytic markers such as SOX10 and HMB45, which are typically negative in MH. Histiocytic sarcoma presents with large, pleomorphic histiocytic cells, which are positive for CD68, CD163, lysozyme, and CD4 and negative for CD1a (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>D), langerin, MPO, and SOX10. Histiocytic sarcoma should be differentiated from diffuse large B-cell lymphoma or T-cell lymphoma with appropriate lymphocytic markers. Langerhans cell sarcoma expresses CD1a, S100, langerin, vimentin, CD68, and BCL1; its histologic features may overlap with those of other histiocytic malignancies. Indeterminate dendritic cell tumor typically involves the skin, sparing the epidermis. The tumor cells resemble Langerhans cells, expressing CD1a and S100, but are negative for langerin, and Birbeck granules are absent. Interdigitating dendritic cell sarcoma features pleomorphic spindle to epithelioid cells that are arranged in sheets or fascicles. The tumor cells are positive for S100, CD68, CD4, CD45, lysozyme, and beta-catenin and lack well-formed desmosomes and Birbeck granules (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A-C) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p><p>
<fig id="Fig6"><label>Fig. 6</label><caption><p>Interdigitating dendritic cell sarcoma. (<bold>A</bold>) Low-power view reveals sheets of spindle cells arranged in fascicles with a whorled pattern. (<bold>B</bold>) High-power view reveals tumor cells with abundant, slightly eosinophilic cytoplasm lacking distinct cell borders. (<bold>C</bold>) S100 protein is diffusely positive</p></caption><graphic xlink:href="12105_2025_1766_Fig6_HTML" id="d33e1043"/></fig>
</p><p>The histological features of secondary MH are similar to those of primary MH. Immunohistochemical staining is essential to confirm the histiocytic origin and distinguish secondary MH from other malignancies. Markers such as CD68, CD163, and lysozyme are typically positive, while markers for the primary malignancy may be absent [<xref ref-type="bibr" rid="CR43">43</xref>].</p><p>Molecular testing is crucial in diagnosing, classifying, and treating MH. Mutations in the MAPK pathway, including <italic>BRAF</italic>, <italic>MAP2K1</italic>, <italic>KRAS</italic>, and <italic>NRAS</italic>, are frequently observed in MH. These mutations lead to constitutive activation of the pathway, promoting uncontrolled cell proliferation. Activating mutations in the <italic>CSF1R</italic>, encoding the colony-stimulating factor 1 receptor, have been identified in histiocytic neoplasms, suggesting a role in disease development and potential therapeutic targeting [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="FPar25"><title>Treatment</title><p id="Par68">Due to the rarity and heterogeneity of MH, standardized treatment protocols have yet to be established, and therapeutic strategies are often individualized based on disease presentation and molecular characteristics [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Chemotherapy and surgery have been the most common first-line treatments for multifocal and unifocal disease, respectively. Targeted therapies are administered based on specific molecular aberrations; for instance, patients harboring <italic>BRAF</italic> V600E mutations may be treated with BRAF inhibitors like vemurafenib [<xref ref-type="bibr" rid="CR43">43</xref>]. Agents targeting immune checkpoints, like PD-1 inhibitors, are being explored, especially in cases exhibiting relevant molecular markers [<xref ref-type="bibr" rid="CR45">45</xref>].</p></sec><sec id="FPar26"><title>Prognosis</title><p id="Par69">The prognosis of MH, like that of many other histiocytic neoplasms, is variable, and is strongly tied to the disease extent and the type of organ involvement. Patients with multifocal disease have a poorer prognosis than those with less disseminated disease [<xref ref-type="bibr" rid="CR40">40</xref>].</p></sec></sec><sec id="Sec8"><title>Primary and Secondary Hemophagocytic Lymphohistiocytosis</title><p id="Par70">HLH is a severe, life-threatening hyperinflammatory syndrome characterized by excessive immune activation, leading to macrophages engulfing blood cells (hemophagocytosis) within organs like the liver, spleen, and bone marrow [<xref ref-type="bibr" rid="CR46">46</xref>]. It can be familial, due to genetic mutations affecting immune regulation, or acquired, triggered by infections, malignancies, or autoimmune conditions [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p><sec id="FPar27"><title>Epidemiology</title><p id="Par71">Approximately 25% of reported HLH cases are primary (familial) HLH, predominantly occurring in infants under one year old. The prevalence and incidence of HLH vary widely across regions. Secondary HLH usually presents in children older than 1 year and in adults. The incidence and prevalence of HLH in adults is unclear. In adult HLH, the most common associated conditions have been reported as malignancy (30.7%), infections (24.3%), autoimmune conditions (20.8%), organ transplant (4%), and congenital immunodeficiency syndromes (2.5%) [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec><sec id="FPar28"><title>Clinical Presentation</title><p id="Par72">HLH is a rare, life-threatening state of immune hyperactivation requiring rapid diagnosis and treatment. HLH presents with a constellation of symptoms driven by an overactive immune response, including prolonged fever, hepatosplenomegaly, cytopenias, hyperferritinemia, hypertriglyceridemia, and hypofibrinogenemia, which indicate severe inflammation and coagulopathy. Severe systemic inflammation may result in altered mental status, respiratory distress syndrome, acute renal failure, or acute liver failure [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="FPar29"><title>Pathogenesis</title><p id="Par73">Primary HLH is a genetically driven immune disorder where the mutations impair cytotoxic function, leading to uncontrolled immune activation and inflammation. Key genes involved in HLH include <italic>PRF1</italic>, <italic>UNC13D</italic>, <italic>STX11</italic>, and <italic>STXBP2</italic>. These genetic mutations impair and disrupt the interaction between CD8&#x02009;+&#x02009;cytotoxic T cells, antigen-presenting cells, and natural-killer (NK) cells, resulting in the overproduction of pro-inflammatory cytokines. Interferon-gamma (IFN-&#x003b3;), interleukin-1-beta (IL-1&#x003b2;), and interleukin-18 (IL-18) appear to be the key soluble mediators of HLH immunopathology. This dysregulation activates macrophages, resulting in subsequent cellular destruction [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p>Secondary HLH is commonly triggered by malignancies, infections (especially Epstein-Barr virus), or autoimmune diseases like systemic lupus erythematosus and juvenile idiopathic arthritis, where it is termed macrophage activation syndrome. The interaction between NK and CD8&#x02009;+&#x02009;cytotoxic T-cell in HLH leads to a fulminant inflammatory response, constantly recruiting additional cytotoxic cells to remove pathologic antigens, resulting in a massive increase in cytokines. Characteristically, in HLH these pathologic, extraneous cytokines promote the further activation of macrophages, resulting in widespread hemophagocytosis and organ-damaging disease [<xref ref-type="bibr" rid="CR47">47</xref>].</p></sec><sec id="FPar55"><title>Diagnosis</title><p id="Par75">Diagnosing HLH relies on a combination of clinical criteria and laboratory findings due to its overlapping symptoms with other inflammatory conditions. The most widely used diagnostic criteria came from the HLH-2004 Diagnostic and Therapeutic Guidelines. Accordingly, the diagnosis of HLH can be established by molecular diagnostic testing consistent with HLH or by meeting five of the following eight criteria: fever, splenomegaly, cytopenias affecting two or more cell lineages, hypertriglyceridemia and/or hypofibrinogenemia, hemophagocytosis, hyperferritinemia, high sIL-2R levels, and low to absent NK cell activity [<xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par76">Histopathologically, HLH reveals hallmark findings of hemophagocytosis, with activated macrophages engulfing blood cells (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A and B) in tissues such as bone marrow, liver (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>C and D), spleen, and lymph nodes. However, hemophagocytosis is not specific to HLH and may be absent in the early stages, making it a supportive but nondefinitive diagnostic feature. Histopathological evaluation must be correlated with clinical and laboratory findings for accurate diagnosis.</p><p>
<fig id="Fig7"><label>Fig. 7</label><caption><p>Familial hemophagocytic lymphohistiocytosis. (<bold>A</bold>) A case of familial hemophagocytic lymphohistiocytosis shows numerous histiocytes with engulfed red blood cells. (<bold>B</bold>) High-power view shows histiocytes with numerous engulfed red blood cells. Image from Wang G. Langerhans Cell Histiocytosis, in DP: Molecular Oncology, 3e, by Vasef M, et al. Copyright Elsevier 2024. Reused with permission. (<bold>C</bold>) A liver biopsy shows sinusoidal histiocytic infiltrate with hemophagocytosis. (<bold>D</bold>) CD163 highlights marked sinusoidal histiocytic infiltrates in the liver</p></caption><graphic xlink:href="12105_2025_1766_Fig7_HTML" id="d33e1194"/></fig>
</p><p>Molecular assays in HLH are used to identify genetic mutations associated with primary HLH. Sequencing of genes commonly associated with primary HLH, such as <italic>PRF1</italic>, <italic>UNC13D</italic>, <italic>STX11</italic>, and <italic>STXBP2</italic>, helps confirm a hereditary basis for the disease [<xref ref-type="bibr" rid="CR50">50</xref>].</p></sec><sec id="FPar30"><title>Treatment</title><p id="Par79">HLH treatment aims to suppress the overactive immune response and manage underlying triggers. Standard treatment typically follows the HLH-2004 Guidelines, which include use of immunosuppressive agents to control inflammation. For primary HLH, hematopoietic stem cell transplantation (HSCT) to replace the defective immune cells is the only curative option. Emapalumab, a monoclonal antibody targeting interferon-gamma (IFN-&#x003b3;), a key cytokine in HLH pathogenesis, has received FDA approval for pediatric and adult patients with primary HLH who have refractory or recurrent disease or who cannot tolerate conventional therapy [<xref ref-type="bibr" rid="CR51">51</xref>]. Secondary HLH, triggered by infections, malignancies, or autoimmune conditions, requires both HLH-directed therapy and treatment of the underlying cause [<xref ref-type="bibr" rid="CR50">50</xref>].</p></sec><sec id="FPar31"><title>Prognosis</title><p id="Par80">Without treatment, primary HLH is typically fatal. Early diagnosis and initiation of therapy are crucial for improving outcomes. Since secondary HLH is triggered by infections, malignancies, or autoimmune diseases, the prognosis depends on the rapid identification and management of the underlying cause. Infection-associated HLH, particularly when promptly treated, can have a favorable outcome. However, malignancy associated HLH often presents a more challenging prognosis due to the aggressive nature of the underlying disease [<xref ref-type="bibr" rid="CR50">50</xref>]. Regardless of etiology, HLH remains a life-threatening condition requiring early recognition and aggressive management to enhance patient outcomes.</p></sec></sec><sec id="Sec9"><title>ALK-positive Histiocytosis</title><p id="Par81">Anaplastic lymphoma kinase (ALK)-positive histiocytosis is a rare histiocytic neoplasm characterized by <italic>ALK</italic> rearrangements within histiocytes. This entity was not included in the revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages by the Histiocyte Society in 2016. Now, ALK-positive histiocytosis is a new entity in the 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms [<xref ref-type="bibr" rid="CR52">52</xref>].</p><sec id="FPar32"><title>Epidemiology</title><p id="Par82">First described in 2008 [<xref ref-type="bibr" rid="CR53">53</xref>], this condition has been identified across a broad age range, from infants to adults, and can manifest as either localized or multisystem disease.</p></sec><sec id="FPar33"><title>Clinical Presentation</title><p id="Par83">Common clinical presentations include involvement of the liver, hematopoietic system, central nervous system, and skin.</p><p><bold>Pathogenesis</bold>: ALK-positive histiocytosis is driven by genetic alterations involving the <italic>ALK</italic>. Most cases are associated with <italic>ALK</italic> fusions, such as <italic>KIF5B::ALK</italic> or other partner genes. These fusion genes lead to constitutive activation of the ALK protein, even without its ligand. These alterations lead to constitutive activation of oncogenic pathways, including RAS/RAF/MEK/ERK, JAK/STAT, PLC-&#x003b3;, and PI3K/AKT, resulting in the clonal proliferation of abnormal histiocytes.</p><p><bold>Diagnosis</bold>: Histologically, the neoplastic histiocytes typically exhibit large, pleomorphic, irregularly folded, deeply cleft, or lobulated nuclei, prominent nucleoli, and abundant eosinophilic cytoplasm. These cells may display a spindled or epithelioid morphology and are often intermixed with Touton giant cells and foamy histiocytes. The neoplastic histiocytes exhibit strong expression of ALK protein by immunohistochemistry, and often harbor <italic>ALK</italic> fusions such as <italic>KIF5B::ALK</italic> [<xref ref-type="bibr" rid="CR54">54</xref>]. Histopathological features overlap with those of other histiocytoses, especially with ECD, RDD, and JXG. Therefore, it is prudent to perform ALK IHC or molecular testing for <italic>ALK</italic> rearrangement in histiocytoses.</p></sec><sec id="FPar34"><title>Treatment</title><p id="Par86">Recent studies have demonstrated that patients with ALK-positive histiocytosis respond favorably to ALK inhibitor therapies, leading to significant clinical improvements [<xref ref-type="bibr" rid="CR55">55</xref>].</p></sec><sec id="FPar35"><title>Prognosis</title><p id="Par87">The prognosis for ALK-positive histiocytosis varies depending on the extent of disease involvement, the affected organs, and the treatment response.</p></sec></sec><sec id="Sec10"><title>Conclusion</title><p id="Par88">LCH and other histiocytic lesions represent a diverse spectrum of disorders with varying clinical presentations, histopathological features, and molecular characteristics. These conditions pose significant diagnostic challenges due to overlapping histologic and immunophenotypic features. Recent advancements in molecular diagnostics, especially identifying recurrent genetic mutations such as those in the MAPK pathway, have markedly enhanced our understanding of their pathogenesis. These findings have facilitated more precise classification and have provided avenues for targeted therapeutic approaches, particularly in aggressive or treatment-resistant cases.</p><p id="Par89">The role of eosinophils, while prominent in specific histiocytic lesions, reflects underlying inflammatory processes and underscores the complexity of the immune environment within these disorders. However, not all histiocytic conditions are characterized by eosinophilic infiltration, highlighting the need for careful histopathological and clinical correlation in diagnosis. A multidisciplinary approach integrating clinical, radiological, histopathological, and molecular data remains critical for accurate diagnosis and effective management. Collaboration across specialties, including pathology, radiology, and oncology, will ensure comprehensive evaluation and optimized treatment strategies. Ongoing research into molecular pathways holds the promise of novel therapeutic developments needed to improve outcomes in patients with these challenging conditions.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The views expressed by the authors are theirs and do not reflect the official policy of the Army/Navy/Air Force, Department of Defense, or U.S. Government.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>McKinney: First draftWang: Final draft and figures.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by SCELC, Statewide California Electronic Library Consortium</p><p>This study was not supported by any funding.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes notes-type="data-availability"><title>Code Availability</title><p>Not applicable.</p></notes><notes><title>Declarations</title><notes id="FPar38" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par90">The authors declare that they have no conflict of interest.</p></notes><notes id="FPar39"><title>Ethical Approval</title><p id="Par91">This article does not contain any studies with human participants or animals performed by any of the authors.</p></notes><notes id="FPar40"><title>Informed Consent</title><p id="Par92">For this type of study informed consent was not required.</p></notes><notes id="FPar36"><title>Consent for Publication</title><p id="Par93">For this type of study consent for publication was not required.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Emile</surname><given-names>JF</given-names></name><name><surname>Abla</surname><given-names>O</given-names></name><name><surname>Fraitag</surname><given-names>S</given-names></name><name><surname>Horne</surname><given-names>A</given-names></name><name><surname>Haroche</surname><given-names>J</given-names></name><name><surname>Donadieu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages</article-title><source>Blood</source><year>2016</year><volume>127</volume><issue>22</issue><fpage>2672</fpage><lpage>2681</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-01-690636</pub-id><pub-id pub-id-type="pmid">26966089</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J et al (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127(22):2672&#x02013;2681<pub-id pub-id-type="pmid">26966089</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Badalian-Very</surname><given-names>G</given-names></name><name><surname>Vergilio</surname><given-names>JA</given-names></name><name><surname>Degar</surname><given-names>BA</given-names></name><name><surname>MacConaill</surname><given-names>LE</given-names></name><name><surname>Brandner</surname><given-names>B</given-names></name><name><surname>Calicchio</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Recurrent BRAF mutations in Langerhans cell histiocytosis</article-title><source>Blood</source><year>2010</year><volume>116</volume><issue>11</issue><fpage>1919</fpage><lpage>1923</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-04-279083</pub-id><pub-id pub-id-type="pmid">20519626</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML et al (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116(11):1919&#x02013;1923<pub-id pub-id-type="pmid">20519626</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Chakraborty R, Abdel-Wahab O, Durham BH (2021) MAP-Kinase-driven hematopoietic neoplasms: a decade of Progress in the Molecular Age. Cold Spring Harb Perspect Med;11(5)</mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Guyot-Goubin</surname><given-names>A</given-names></name><name><surname>Donadieu</surname><given-names>J</given-names></name><name><surname>Barkaoui</surname><given-names>M</given-names></name><name><surname>Bellec</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Clavel</surname><given-names>J</given-names></name></person-group><article-title>Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000&#x02013;2004</article-title><source>Pediatr Blood Cancer</source><year>2008</year><volume>51</volume><issue>1</issue><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1002/pbc.21498</pub-id><pub-id pub-id-type="pmid">18260117</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J (2008) Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000&#x02013;2004. Pediatr Blood Cancer 51(1):71&#x02013;75<pub-id pub-id-type="pmid">18260117</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Salotti</surname><given-names>JA</given-names></name><name><surname>Nanduri</surname><given-names>V</given-names></name><name><surname>Pearce</surname><given-names>MS</given-names></name><name><surname>Parker</surname><given-names>L</given-names></name><name><surname>Lynn</surname><given-names>R</given-names></name><name><surname>Windebank</surname><given-names>KP</given-names></name></person-group><article-title>Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland</article-title><source>Arch Dis Child</source><year>2009</year><volume>94</volume><issue>5</issue><fpage>376</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1136/adc.2008.144527</pub-id><pub-id pub-id-type="pmid">19060008</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Salotti JA, Nanduri V, Pearce MS, Parker L, Lynn R, Windebank KP (2009) Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child 94(5):376&#x02013;380<pub-id pub-id-type="pmid">19060008</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Buhtoiarov</surname><given-names>IN</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Radivoyevitch</surname><given-names>T</given-names></name><name><surname>Incidence</surname></name></person-group><article-title>Clinical features, and outcomes of Langerhans Cell Histiocytosis in the United States</article-title><source>J Pediatr Hematol Oncol</source><year>2022</year><volume>44</volume><issue>7</issue><fpage>e1006</fpage><lpage>e15</lpage><pub-id pub-id-type="doi">10.1097/MPH.0000000000002383</pub-id><pub-id pub-id-type="pmid">35082244</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Buhtoiarov IN, Mukherjee S, Radivoyevitch T, Incidence (2022) Clinical features, and outcomes of Langerhans Cell Histiocytosis in the United States. J Pediatr Hematol Oncol 44(7):e1006&#x02013;e15<pub-id pub-id-type="pmid">35082244</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Jezierska</surname><given-names>M</given-names></name><name><surname>Stefanowicz</surname><given-names>J</given-names></name><name><surname>Romanowicz</surname><given-names>G</given-names></name><name><surname>Kosiak</surname><given-names>W</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name></person-group><article-title>Langerhans cell histiocytosis in children - a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment</article-title><source>Postepy Dermatol Alergol</source><year>2018</year><volume>35</volume><issue>1</issue><fpage>6</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.5114/pdia.2017.67095</pub-id><pub-id pub-id-type="pmid">29599667</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Jezierska M, Stefanowicz J, Romanowicz G, Kosiak W, Lange M (2018) Langerhans cell histiocytosis in children - a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment. Postepy Dermatol Alergol 35(1):6&#x02013;17<pub-id pub-id-type="pmid">29599667</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Galindo</surname><given-names>C</given-names></name><name><surname>Allen</surname><given-names>CE</given-names></name></person-group><source>Langerhans cell Histiocytosis Blood</source><year>2020</year><volume>135</volume><issue>16</issue><fpage>1319</fpage><lpage>1331</lpage><pub-id pub-id-type="pmid">32106306</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Rodriguez-Galindo C, Allen CE (2020) Langerhans cell Histiocytosis Blood 135(16):1319&#x02013;1331<pub-id pub-id-type="pmid">32106306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>JS</given-names></name><name><surname>Harty</surname><given-names>MP</given-names></name><name><surname>Mahboubi</surname><given-names>S</given-names></name><name><surname>Heyman</surname><given-names>S</given-names></name><name><surname>Zimmerman</surname><given-names>RA</given-names></name><name><surname>Womer</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Langerhans cell histiocytosis: presentation and evolution of radiologic findings with clinical correlation</article-title><source>Radiographics</source><year>1995</year><volume>15</volume><issue>5</issue><fpage>1135</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1148/radiographics.15.5.7501855</pub-id><pub-id pub-id-type="pmid">7501855</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Meyer JS, Harty MP, Mahboubi S, Heyman S, Zimmerman RA, Womer RB et al (1995) Langerhans cell histiocytosis: presentation and evolution of radiologic findings with clinical correlation. Radiographics 15(5):1135&#x02013;1146<pub-id pub-id-type="pmid">7501855</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Ambrosio</surname><given-names>N</given-names></name><name><surname>Soohoo</surname><given-names>S</given-names></name><name><surname>Warshall</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>A</given-names></name><name><surname>Karimi</surname><given-names>S</given-names></name></person-group><article-title>Craniofacial and intracranial manifestations of langerhans cell histiocytosis: report of findings in 100 patients</article-title><source>AJR Am J Roentgenol</source><year>2008</year><volume>191</volume><issue>2</issue><fpage>589</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.2214/AJR.07.3573</pub-id><pub-id pub-id-type="pmid">18647937</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">D&#x02019;Ambrosio N, Soohoo S, Warshall C, Johnson A, Karimi S (2008) Craniofacial and intracranial manifestations of langerhans cell histiocytosis: report of findings in 100 patients. AJR Am J Roentgenol 191(2):589&#x02013;597<pub-id pub-id-type="pmid">18647937</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Kilpatrick</surname><given-names>SE</given-names></name><name><surname>Wenger</surname><given-names>DE</given-names></name><name><surname>Gilchrist</surname><given-names>GS</given-names></name><name><surname>Shives</surname><given-names>TC</given-names></name><name><surname>Wollan</surname><given-names>PC</given-names></name><name><surname>Unni</surname><given-names>KK</given-names></name></person-group><article-title>Langerhans&#x02019; cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases</article-title><source>Cancer</source><year>1995</year><volume>76</volume><issue>12</issue><fpage>2471</fpage><lpage>2484</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19951215)76:12&#x0003c;2471::AID-CNCR2820761211&#x0003e;3.0.CO;2-Z</pub-id><pub-id pub-id-type="pmid">8625073</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kilpatrick SE, Wenger DE, Gilchrist GS, Shives TC, Wollan PC, Unni KK (1995) Langerhans&#x02019; cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer 76(12):2471&#x02013;2484<pub-id pub-id-type="pmid">8625073</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>G</given-names></name><name><surname>Tazi</surname><given-names>A</given-names></name><name><surname>Go</surname><given-names>RS</given-names></name><name><surname>Rech</surname><given-names>KL</given-names></name><name><surname>Picarsic</surname><given-names>JL</given-names></name><name><surname>Vassallo</surname><given-names>R</given-names></name><etal/></person-group><article-title>International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults</article-title><source>Blood</source><year>2022</year><volume>139</volume><issue>17</issue><fpage>2601</fpage><lpage>2621</lpage><pub-id pub-id-type="doi">10.1182/blood.2021014343</pub-id><pub-id pub-id-type="pmid">35271698</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Goyal G, Tazi A, Go RS, Rech KL, Picarsic JL, Vassallo R et al (2022) International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood 139(17):2601&#x02013;2621<pub-id pub-id-type="pmid">35271698</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Jouenne</surname><given-names>FB</given-names></name><name><surname>Tazi</surname><given-names>A</given-names></name></person-group><article-title>Pulmonary langerhans cell histiocytosis - an update on pathogenesis and treatment</article-title><source>Curr Opin Pulm Med</source><year>2023</year><volume>29</volume><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">37410483</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Jouenne FB, Tazi A (2023) Pulmonary langerhans cell histiocytosis - an update on pathogenesis and treatment. Curr Opin Pulm Med 29:451&#x02013;458<pub-id pub-id-type="pmid">37410483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>KPH</given-names></name><name><surname>Milne</surname><given-names>P</given-names></name><name><surname>Poidinger</surname><given-names>M</given-names></name><name><surname>Duan</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>McGovern</surname><given-names>N</given-names></name><etal/></person-group><article-title>Circulating CD1c&#x02009;+&#x02009;myeloid dendritic cells are potential precursors to LCH lesion CD1a&#x02009;+&#x02009;CD207&#x02009;+&#x02009;cells</article-title><source>Blood Adv</source><year>2020</year><volume>4</volume><issue>1</issue><fpage>87</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2019000488</pub-id><pub-id pub-id-type="pmid">31899802</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Lim KPH, Milne P, Poidinger M, Duan K, Lin H, McGovern N et al (2020) Circulating CD1c&#x02009;+&#x02009;myeloid dendritic cells are potential precursors to LCH lesion CD1a&#x02009;+&#x02009;CD207&#x02009;+&#x02009;cells. Blood Adv 4(1):87&#x02013;99<pub-id pub-id-type="pmid">31899802</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Willman</surname><given-names>CL</given-names></name><name><surname>Busque</surname><given-names>L</given-names></name><name><surname>Griffith</surname><given-names>BB</given-names></name><name><surname>Favara</surname><given-names>BE</given-names></name><name><surname>McClain</surname><given-names>KL</given-names></name><name><surname>Duncan</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Langerhans&#x02019;-cell histiocytosis (histiocytosis X)- -a clonal proliferative disease</article-title><source>N Engl J Med</source><year>1994</year><volume>331</volume><issue>3</issue><fpage>154</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1056/NEJM199407213310303</pub-id><pub-id pub-id-type="pmid">8008029</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH et al (1994) Langerhans&#x02019;-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med 331(3):154&#x02013;160<pub-id pub-id-type="pmid">8008029</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname><given-names>R</given-names></name><name><surname>Hampton</surname><given-names>OA</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Simko</surname><given-names>SJ</given-names></name><name><surname>Shih</surname><given-names>A</given-names></name><name><surname>Abhyankar</surname><given-names>H</given-names></name><etal/></person-group><article-title>Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis</article-title><source>Blood</source><year>2014</year><volume>124</volume><issue>19</issue><fpage>3007</fpage><lpage>3015</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-05-577825</pub-id><pub-id pub-id-type="pmid">25202140</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H et al (2014) Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124(19):3007&#x02013;3015<pub-id pub-id-type="pmid">25202140</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>DS</given-names></name><name><surname>van Halteren</surname><given-names>A</given-names></name><name><surname>Quispel</surname><given-names>WT</given-names></name><name><surname>van den Bos</surname><given-names>C</given-names></name><name><surname>Bovee</surname><given-names>JV</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><etal/></person-group><article-title>MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis</article-title><source>Genes Chromosomes Cancer</source><year>2015</year><volume>54</volume><issue>6</issue><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1002/gcc.22247</pub-id><pub-id pub-id-type="pmid">25899310</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovee JV, Patel B et al (2015) MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 54(6):361&#x02013;368<pub-id pub-id-type="pmid">25899310</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Durham</surname><given-names>BH</given-names></name><name><surname>Lopez Rodrigo</surname><given-names>E</given-names></name><name><surname>Picarsic</surname><given-names>J</given-names></name><name><surname>Abramson</surname><given-names>D</given-names></name><name><surname>Rotemberg</surname><given-names>V</given-names></name><name><surname>De Munck</surname><given-names>S</given-names></name><etal/></person-group><article-title>Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms</article-title><source>Nat Med</source><year>2019</year><volume>25</volume><issue>12</issue><fpage>1839</fpage><lpage>1842</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0653-6</pub-id><pub-id pub-id-type="pmid">31768065</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S et al (2019) Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med 25(12):1839&#x02013;1842<pub-id pub-id-type="pmid">31768065</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Coury</surname><given-names>F</given-names></name><name><surname>Annels</surname><given-names>N</given-names></name><name><surname>Rivollier</surname><given-names>A</given-names></name><name><surname>Olsson</surname><given-names>S</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Speziani</surname><given-names>C</given-names></name><etal/></person-group><article-title>Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion</article-title><source>Nat Med</source><year>2008</year><volume>14</volume><issue>1</issue><fpage>81</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1038/nm1694</pub-id><pub-id pub-id-type="pmid">18157139</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C et al (2008) Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med 14(1):81&#x02013;87<pub-id pub-id-type="pmid">18157139</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Annels</surname><given-names>NE</given-names></name><name><surname>Da Costa</surname><given-names>CE</given-names></name><name><surname>Prins</surname><given-names>FA</given-names></name><name><surname>Willemze</surname><given-names>A</given-names></name><name><surname>Hogendoorn</surname><given-names>PC</given-names></name><name><surname>Egeler</surname><given-names>RM</given-names></name></person-group><article-title>Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis</article-title><source>J Exp Med</source><year>2003</year><volume>197</volume><issue>10</issue><fpage>1385</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1084/jem.20030137</pub-id><pub-id pub-id-type="pmid">12743170</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Annels NE, Da Costa CE, Prins FA, Willemze A, Hogendoorn PC, Egeler RM (2003) Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med 197(10):1385&#x02013;1390<pub-id pub-id-type="pmid">12743170</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Sconocchia</surname><given-names>T</given-names></name><name><surname>Fosselteder</surname><given-names>J</given-names></name><name><surname>Sconocchia</surname><given-names>G</given-names></name><name><surname>Reinisch</surname><given-names>A</given-names></name></person-group><article-title>Langerhans cell histiocytosis: current advances in molecular pathogenesis</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1275085</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1275085</pub-id><pub-id pub-id-type="pmid">37965340</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Sconocchia T, Fosselteder J, Sconocchia G, Reinisch A (2023) Langerhans cell histiocytosis: current advances in molecular pathogenesis. Front Immunol 14:1275085<pub-id pub-id-type="pmid">37965340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Haupt</surname><given-names>R</given-names></name><name><surname>Minkov</surname><given-names>M</given-names></name><name><surname>Astigarraga</surname><given-names>I</given-names></name><name><surname>Schafer</surname><given-names>E</given-names></name><name><surname>Nanduri</surname><given-names>V</given-names></name><name><surname>Jubran</surname><given-names>R</given-names></name><etal/></person-group><article-title>Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years</article-title><source>Pediatr Blood Cancer</source><year>2013</year><volume>60</volume><issue>2</issue><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1002/pbc.24367</pub-id><pub-id pub-id-type="pmid">23109216</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Haupt R, Minkov M, Astigarraga I, Schafer E, Nanduri V, Jubran R et al (2013) Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer 60(2):175&#x02013;184<pub-id pub-id-type="pmid">23109216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Emile</surname><given-names>JF</given-names></name><name><surname>Helias-Rodzewicz</surname><given-names>Z</given-names></name><name><surname>Durham</surname><given-names>BH</given-names></name><name><surname>Heritier</surname><given-names>S</given-names></name><name><surname>da Silva</surname><given-names>M</given-names></name><name><surname>Younas</surname><given-names>K</given-names></name><etal/></person-group><article-title>Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type</article-title><source>Blood Adv</source><year>2023</year><volume>7</volume><issue>23</issue><fpage>7254</fpage><lpage>7257</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2023011414</pub-id><pub-id pub-id-type="pmid">37878806</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Emile JF, Helias-Rodzewicz Z, Durham BH, Heritier S, da Silva M, Younas K et al (2023) Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type. Blood Adv 7(23):7254&#x02013;7257<pub-id pub-id-type="pmid">37878806</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Emile</surname><given-names>JF</given-names></name><name><surname>Cohen-Aubart</surname><given-names>F</given-names></name><name><surname>Collin</surname><given-names>M</given-names></name><name><surname>Fraitag</surname><given-names>S</given-names></name><name><surname>Idbaih</surname><given-names>A</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><etal/></person-group><source>Histiocytosis Lancet</source><year>2021</year><volume>398</volume><issue>10295</issue><fpage>157</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00311-1</pub-id><pub-id pub-id-type="pmid">33901419</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Emile JF, Cohen-Aubart F, Collin M, Fraitag S, Idbaih A, Abdel-Wahab O et al (2021) Histiocytosis Lancet 398(10295):157&#x02013;170<pub-id pub-id-type="pmid">33901419</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>G</given-names></name><name><surname>Acosta-Medina</surname><given-names>AA</given-names></name><name><surname>Abeykoon</surname><given-names>JP</given-names></name><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Ravindran</surname><given-names>A</given-names></name><name><surname>Vassallo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Long-term outcomes among adults with Langerhans cell histiocytosis</article-title><source>Blood Adv</source><year>2023</year><volume>7</volume><issue>21</issue><fpage>6568</fpage><lpage>6578</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2023010706</pub-id><pub-id pub-id-type="pmid">37698994</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Goyal G, Acosta-Medina AA, Abeykoon JP, Dai C, Ravindran A, Vassallo R et al (2023) Long-term outcomes among adults with Langerhans cell histiocytosis. Blood Adv 7(21):6568&#x02013;6578<pub-id pub-id-type="pmid">37698994</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Hervier</surname><given-names>B</given-names></name><name><surname>Haroche</surname><given-names>J</given-names></name><name><surname>Arnaud</surname><given-names>L</given-names></name><name><surname>Charlotte</surname><given-names>F</given-names></name><name><surname>Donadieu</surname><given-names>J</given-names></name><name><surname>Neel</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation</article-title><source>Blood</source><year>2014</year><volume>124</volume><issue>7</issue><fpage>1119</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-12-543793</pub-id><pub-id pub-id-type="pmid">24894769</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, Neel A et al (2014) Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 124(7):1119&#x02013;1126<pub-id pub-id-type="pmid">24894769</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Estrada-Veras</surname><given-names>JI</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>KJ</given-names></name><name><surname>Boyd</surname><given-names>LC</given-names></name><name><surname>Dave</surname><given-names>RH</given-names></name><name><surname>Durham</surname><given-names>B</given-names></name><name><surname>Xi</surname><given-names>L</given-names></name><etal/></person-group><article-title>The clinical spectrum of Erdheim-Chester disease: an observational cohort study</article-title><source>Blood Adv</source><year>2017</year><volume>1</volume><issue>6</issue><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2016001784</pub-id><pub-id pub-id-type="pmid">28553668</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Estrada-Veras JI, O&#x02019;Brien KJ, Boyd LC, Dave RH, Durham B, Xi L et al (2017) The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv 1(6):357&#x02013;366<pub-id pub-id-type="pmid">28553668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>EL</given-names></name><name><surname>Dagna</surname><given-names>L</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name><name><surname>Cavalli</surname><given-names>G</given-names></name><name><surname>Janku</surname><given-names>F</given-names></name><name><surname>Estrada-Veras</surname><given-names>J</given-names></name><etal/></person-group><article-title>Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease</article-title><source>Blood</source><year>2014</year><volume>124</volume><issue>4</issue><fpage>483</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-03-561381</pub-id><pub-id pub-id-type="pmid">24850756</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J et al (2014) Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124(4):483&#x02013;492<pub-id pub-id-type="pmid">24850756</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Haroche</surname><given-names>J</given-names></name><name><surname>Charlotte</surname><given-names>F</given-names></name><name><surname>Arnaud</surname><given-names>L</given-names></name><name><surname>von Deimling</surname><given-names>A</given-names></name><name><surname>Helias-Rodzewicz</surname><given-names>Z</given-names></name><name><surname>Hervier</surname><given-names>B</given-names></name><etal/></person-group><article-title>High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-langerhans cell histiocytoses</article-title><source>Blood</source><year>2012</year><volume>120</volume><issue>13</issue><fpage>2700</fpage><lpage>2703</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-05-430140</pub-id><pub-id pub-id-type="pmid">22879539</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias-Rodzewicz Z, Hervier B et al (2012) High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-langerhans cell histiocytoses. Blood 120(13):2700&#x02013;2703<pub-id pub-id-type="pmid">22879539</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>EL</given-names></name><name><surname>Durham</surname><given-names>BH</given-names></name><name><surname>Haroche</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Parikh</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Diverse and targetable kinase alterations drive histiocytic neoplasms</article-title><source>Cancer Discov</source><year>2016</year><volume>6</volume><issue>2</issue><fpage>154</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0913</pub-id><pub-id pub-id-type="pmid">26566875</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA et al (2016) Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 6(2):154&#x02013;165<pub-id pub-id-type="pmid">26566875</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>G</given-names></name><name><surname>Heaney</surname><given-names>ML</given-names></name><name><surname>Collin</surname><given-names>M</given-names></name><name><surname>Cohen-Aubart</surname><given-names>F</given-names></name><name><surname>Vaglio</surname><given-names>A</given-names></name><name><surname>Durham</surname><given-names>BH</given-names></name><etal/></person-group><article-title>Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era</article-title><source>Blood</source><year>2020</year><volume>135</volume><issue>22</issue><fpage>1929</fpage><lpage>1945</lpage><pub-id pub-id-type="doi">10.1182/blood.2019003507</pub-id><pub-id pub-id-type="pmid">32187362</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH et al (2020) Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood 135(22):1929&#x02013;1945<pub-id pub-id-type="pmid">32187362</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Ozkaya</surname><given-names>N</given-names></name><name><surname>Rosenblum</surname><given-names>MK</given-names></name><name><surname>Durham</surname><given-names>BH</given-names></name><name><surname>Pichardo</surname><given-names>JD</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Hameed</surname><given-names>MR</given-names></name><etal/></person-group><article-title>The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort</article-title><source>Mod Pathol</source><year>2018</year><volume>31</volume><issue>4</issue><fpage>581</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2017.160</pub-id><pub-id pub-id-type="pmid">29192649</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Ozkaya N, Rosenblum MK, Durham BH, Pichardo JD, Abdel-Wahab O, Hameed MR et al (2018) The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol 31(4):581&#x02013;597<pub-id pub-id-type="pmid">29192649</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Luder</surname><given-names>CM</given-names></name><name><surname>Nordmann</surname><given-names>TM</given-names></name><name><surname>Ramelyte</surname><given-names>E</given-names></name><name><surname>Muhleisen</surname><given-names>B</given-names></name><name><surname>Kerl</surname><given-names>K</given-names></name><name><surname>Guenova</surname><given-names>E</given-names></name><etal/></person-group><article-title>Histiocytosis - cutaneous manifestations of hematopoietic neoplasm and non-neoplastic histiocytic proliferations</article-title><source>J Eur Acad Dermatol Venereol</source><year>2018</year><volume>32</volume><issue>6</issue><fpage>926</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1111/jdv.14794</pub-id><pub-id pub-id-type="pmid">29341328</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Luder CM, Nordmann TM, Ramelyte E, Muhleisen B, Kerl K, Guenova E et al (2018) Histiocytosis - cutaneous manifestations of hematopoietic neoplasm and non-neoplastic histiocytic proliferations. J Eur Acad Dermatol Venereol 32(6):926&#x02013;934<pub-id pub-id-type="pmid">29341328</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Fraitag</surname><given-names>S</given-names></name><name><surname>Emile</surname><given-names>JF</given-names></name></person-group><article-title>Cutaneous histiocytoses in children</article-title><source>Histopathology</source><year>2022</year><volume>80</volume><issue>1</issue><fpage>196</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1111/his.14569</pub-id><pub-id pub-id-type="pmid">34958507</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Fraitag S, Emile JF (2022) Cutaneous histiocytoses in children. Histopathology 80(1):196&#x02013;215<pub-id pub-id-type="pmid">34958507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Bruce-Brand</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>JW</given-names></name><name><surname>Schubert</surname><given-names>P</given-names></name></person-group><article-title>Rosai-Dorfman disease: an overview</article-title><source>J Clin Pathol</source><year>2020</year><volume>73</volume><issue>11</issue><fpage>697</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1136/jclinpath-2020-206733</pub-id><pub-id pub-id-type="pmid">32591351</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Bruce-Brand C, Schneider JW, Schubert P (2020) Rosai-Dorfman disease: an overview. J Clin Pathol 73(11):697&#x02013;705<pub-id pub-id-type="pmid">32591351</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Abla</surname><given-names>O</given-names></name><name><surname>Jacobsen</surname><given-names>E</given-names></name><name><surname>Picarsic</surname><given-names>J</given-names></name><name><surname>Krenova</surname><given-names>Z</given-names></name><name><surname>Jaffe</surname><given-names>R</given-names></name><name><surname>Emile</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease</article-title><source>Blood</source><year>2018</year><volume>131</volume><issue>26</issue><fpage>2877</fpage><lpage>2890</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-03-839753</pub-id><pub-id pub-id-type="pmid">29720485</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF et al (2018) Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood 131(26):2877&#x02013;2890<pub-id pub-id-type="pmid">29720485</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Ravindran</surname><given-names>A</given-names></name><name><surname>Rech</surname><given-names>KL</given-names></name></person-group><article-title>How I diagnose Rosai-Dorfman Disease</article-title><source>Am J Clin Pathol</source><year>2023</year><volume>160</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1093/ajcp/aqad047</pub-id><pub-id pub-id-type="pmid">37167084</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Ravindran A, Rech KL (2023) How I diagnose Rosai-Dorfman Disease. Am J Clin Pathol 160(1):1&#x02013;10<pub-id pub-id-type="pmid">37167084</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>KN</given-names></name><name><surname>Yoon</surname><given-names>SH</given-names></name><name><surname>Kang</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Im</surname><given-names>HJ</given-names></name></person-group><article-title>Advancements in the understanding and management of histiocytic neoplasms</article-title><source>Blood Res</source><year>2024</year><volume>59</volume><issue>1</issue><fpage>22</fpage><pub-id pub-id-type="doi">10.1007/s44313-024-00022-w</pub-id><pub-id pub-id-type="pmid">38963520</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Koh KN, Yoon SH, Kang SH, Kim H, Im HJ (2024) Advancements in the understanding and management of histiocytic neoplasms. Blood Res 59(1):22<pub-id pub-id-type="pmid">38963520</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">WHO Classification of Tumors Editorial Board Haematolymphoid tumors [Internet]. Lyon (France): International Agency for Research on Cancer; 2024 [cited 2024 OCT 24]. (WHO classification of tumours series, 5th ed.; vol. 11). Available from: <ext-link ext-link-type="uri" xlink:href="https://tumourclassification.iarc.who.int/chapters/63">https://tumourclassification.iarc.who.int/chapters/63</ext-link></mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>GJ</given-names></name><name><surname>Zanwar</surname><given-names>S</given-names></name><name><surname>Ravindran</surname><given-names>A</given-names></name><name><surname>Schram</surname><given-names>S</given-names></name><name><surname>Abeykoon</surname><given-names>JP</given-names></name><name><surname>Hazim</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis</article-title><source>Am J Hematol</source><year>2024</year><volume>99</volume><issue>5</issue><fpage>871</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1002/ajh.27263</pub-id><pub-id pub-id-type="pmid">38409747</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Ruan GJ, Zanwar S, Ravindran A, Schram S, Abeykoon JP, Hazim A et al (2024) Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis. Am J Hematol 99(5):871&#x02013;879<pub-id pub-id-type="pmid">38409747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Massoth</surname><given-names>LR</given-names></name><name><surname>Hung</surname><given-names>YP</given-names></name><name><surname>Ferry</surname><given-names>JA</given-names></name><name><surname>Hasserjian</surname><given-names>RP</given-names></name><name><surname>Nardi</surname><given-names>V</given-names></name><name><surname>Nielsen</surname><given-names>GP</given-names></name><etal/></person-group><article-title>Histiocytic and dendritic cell sarcomas of hematopoietic origin share Targetable genomic alterations distinct from follicular dendritic cell sarcoma</article-title><source>Oncologist</source><year>2021</year><volume>26</volume><issue>7</issue><fpage>e1263</fpage><lpage>e72</lpage><pub-id pub-id-type="doi">10.1002/onco.13801</pub-id><pub-id pub-id-type="pmid">33904632</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Massoth LR, Hung YP, Ferry JA, Hasserjian RP, Nardi V, Nielsen GP et al (2021) Histiocytic and dendritic cell sarcomas of hematopoietic origin share Targetable genomic alterations distinct from follicular dendritic cell sarcoma. Oncologist 26(7):e1263&#x02013;e72<pub-id pub-id-type="pmid">33904632</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname><given-names>C</given-names></name><name><surname>Nicolae</surname><given-names>A</given-names></name><name><surname>Lack</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>HJ</given-names></name><name><surname>Skarshaug</surname><given-names>S</given-names></name><name><surname>Pham</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups</article-title><source>Haematologica</source><year>2020</year><volume>105</volume><issue>4</issue><fpage>951</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.3324/haematol.2019.230375</pub-id><pub-id pub-id-type="pmid">31439678</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Egan C, Nicolae A, Lack J, Chung HJ, Skarshaug S, Pham TA et al (2020) Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups. Haematologica 105(4):951&#x02013;960<pub-id pub-id-type="pmid">31439678</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>J</given-names></name><name><surname>Naqash</surname><given-names>AR</given-names></name><name><surname>Munker</surname><given-names>R</given-names></name><name><surname>El-Osta</surname><given-names>H</given-names></name><name><surname>Master</surname><given-names>S</given-names></name><name><surname>Cotelingam</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment</article-title><source>Eur J Haematol</source><year>2016</year><volume>97</volume><issue>1</issue><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1111/ejh.12755</pub-id><pub-id pub-id-type="pmid">26990812</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Ansari J, Naqash AR, Munker R, El-Osta H, Master S, Cotelingam JD et al (2016) Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment. Eur J Haematol 97(1):9&#x02013;16<pub-id pub-id-type="pmid">26990812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Ravindran</surname><given-names>A</given-names></name><name><surname>Dasari</surname><given-names>S</given-names></name><name><surname>Ruan</surname><given-names>GJ</given-names></name><name><surname>Artymiuk</surname><given-names>CJ</given-names></name><name><surname>He</surname><given-names>R</given-names></name><name><surname>Viswanatha</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Malignant histiocytosis comprises a phenotypic spectrum that parallels the lineage differentiation of monocytes, macrophages, dendritic cells, and Langerhans Cells</article-title><source>Mod Pathol</source><year>2023</year><volume>36</volume><issue>10</issue><fpage>100268</fpage><pub-id pub-id-type="doi">10.1016/j.modpat.2023.100268</pub-id><pub-id pub-id-type="pmid">37406859</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Ravindran A, Dasari S, Ruan GJ, Artymiuk CJ, He R, Viswanatha DS et al (2023) Malignant histiocytosis comprises a phenotypic spectrum that parallels the lineage differentiation of monocytes, macrophages, dendritic cells, and Langerhans Cells. Mod Pathol 36(10):100268<pub-id pub-id-type="pmid">37406859</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Imataki</surname><given-names>O</given-names></name><name><surname>Uemura</surname><given-names>M</given-names></name><name><surname>Fujita</surname><given-names>H</given-names></name><name><surname>Kadowaki</surname><given-names>N</given-names></name></person-group><article-title>Application of PD-L1 blockade in refractory histiocytic sarcoma: a case report</article-title><source>Mol Clin Oncol</source><year>2022</year><volume>17</volume><issue>3</issue><fpage>136</fpage><pub-id pub-id-type="doi">10.3892/mco.2022.2569</pub-id><pub-id pub-id-type="pmid">35949894</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Imataki O, Uemura M, Fujita H, Kadowaki N (2022) Application of PD-L1 blockade in refractory histiocytic sarcoma: a case report. Mol Clin Oncol 17(3):136<pub-id pub-id-type="pmid">35949894</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>G</given-names></name><name><surname>Shenoi</surname><given-names>S</given-names></name><name><surname>Hughes</surname><given-names>GC</given-names></name></person-group><article-title>Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy</article-title><source>Best Pract Res Clin Rheumatol</source><year>2020</year><volume>34</volume><issue>4</issue><fpage>101515</fpage><pub-id pub-id-type="doi">10.1016/j.berh.2020.101515</pub-id><pub-id pub-id-type="pmid">32387063</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Griffin G, Shenoi S, Hughes GC (2020) Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol 34(4):101515<pub-id pub-id-type="pmid">32387063</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Ponnatt</surname><given-names>TS</given-names></name><name><surname>Lilley</surname><given-names>CM</given-names></name><name><surname>Mirza</surname><given-names>KM</given-names></name></person-group><article-title>Hemophagocytic Lymphohistiocytosis</article-title><source>Arch Pathol Lab Med</source><year>2022</year><volume>146</volume><issue>4</issue><fpage>507</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.5858/arpa.2020-0802-RA</pub-id><pub-id pub-id-type="pmid">34347856</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Ponnatt TS, Lilley CM, Mirza KM (2022) Hemophagocytic Lymphohistiocytosis. Arch Pathol Lab Med 146(4):507&#x02013;519<pub-id pub-id-type="pmid">34347856</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Henter</surname><given-names>JI</given-names></name><name><surname>Horne</surname><given-names>A</given-names></name><name><surname>Arico</surname><given-names>M</given-names></name><name><surname>Egeler</surname><given-names>RM</given-names></name><name><surname>Filipovich</surname><given-names>AH</given-names></name><name><surname>Imashuku</surname><given-names>S</given-names></name><etal/></person-group><article-title>HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis</article-title><source>Pediatr Blood Cancer</source><year>2007</year><volume>48</volume><issue>2</issue><fpage>124</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1002/pbc.21039</pub-id><pub-id pub-id-type="pmid">16937360</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S et al (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124&#x02013;131<pub-id pub-id-type="pmid">16937360</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelhay</surname><given-names>A</given-names></name><name><surname>Mahmoud</surname><given-names>AA</given-names></name><name><surname>Al Ali</surname><given-names>O</given-names></name><name><surname>Hashem</surname><given-names>A</given-names></name><name><surname>Orakzai</surname><given-names>A</given-names></name><name><surname>Jamshed</surname><given-names>S</given-names></name></person-group><article-title>Epidemiology, characteristics, and outcomes of adult haemophagocytic lymphohistiocytosis in the USA, 2006-19: a national, retrospective cohort study</article-title><source>EClinicalMedicine</source><year>2023</year><volume>62</volume><fpage>102143</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2023.102143</pub-id><pub-id pub-id-type="pmid">37599909</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Abdelhay A, Mahmoud AA, Al Ali O, Hashem A, Orakzai A, Jamshed S (2023) Epidemiology, characteristics, and outcomes of adult haemophagocytic lymphohistiocytosis in the USA, 2006-19: a national, retrospective cohort study. EClinicalMedicine 62:102143<pub-id pub-id-type="pmid">37599909</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>La Rosee</surname><given-names>P</given-names></name><name><surname>Horne</surname><given-names>A</given-names></name><name><surname>Hines</surname><given-names>M</given-names></name><name><surname>von Bahr Greenwood</surname><given-names>T</given-names></name><name><surname>Machowicz</surname><given-names>R</given-names></name><name><surname>Berliner</surname><given-names>N</given-names></name><etal/></person-group><article-title>Recommendations for the management of hemophagocytic lymphohistiocytosis in adults</article-title><source>Blood</source><year>2019</year><volume>133</volume><issue>23</issue><fpage>2465</fpage><lpage>2477</lpage><pub-id pub-id-type="doi">10.1182/blood.2018894618</pub-id><pub-id pub-id-type="pmid">30992265</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">La Rosee P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N et al (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133(23):2465&#x02013;2477<pub-id pub-id-type="pmid">30992265</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Vallurupalli</surname><given-names>M</given-names></name><name><surname>Berliner</surname><given-names>N</given-names></name></person-group><article-title>Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis</article-title><source>Blood</source><year>2019</year><volume>134</volume><issue>21</issue><fpage>1783</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1182/blood.2019002289</pub-id><pub-id pub-id-type="pmid">31537529</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Vallurupalli M, Berliner N (2019) Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood 134(21):1783&#x02013;1786<pub-id pub-id-type="pmid">31537529</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Khoury</surname><given-names>JD</given-names></name><name><surname>Solary</surname><given-names>E</given-names></name><name><surname>Abla</surname><given-names>O</given-names></name><name><surname>Akkari</surname><given-names>Y</given-names></name><name><surname>Alaggio</surname><given-names>R</given-names></name><name><surname>Apperley</surname><given-names>JF</given-names></name><etal/></person-group><article-title>The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic neoplasms</article-title><source>Leukemia</source><year>2022</year><volume>36</volume><issue>7</issue><fpage>1703</fpage><lpage>1719</lpage><pub-id pub-id-type="doi">10.1038/s41375-022-01613-1</pub-id><pub-id pub-id-type="pmid">35732831</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic neoplasms. Leukemia 36(7):1703&#x02013;1719<pub-id pub-id-type="pmid">35732831</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JK</given-names></name><name><surname>Lamant</surname><given-names>L</given-names></name><name><surname>Algar</surname><given-names>E</given-names></name><name><surname>Delsol</surname><given-names>G</given-names></name><name><surname>Tsang</surname><given-names>WY</given-names></name><name><surname>Lee</surname><given-names>KC</given-names></name><etal/></person-group><article-title>ALK&#x02009;+&#x02009;histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy</article-title><source>Blood</source><year>2008</year><volume>112</volume><issue>7</issue><fpage>2965</fpage><lpage>2968</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-03-147017</pub-id><pub-id pub-id-type="pmid">18660380</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Chan JK, Lamant L, Algar E, Delsol G, Tsang WY, Lee KC et al (2008) ALK&#x02009;+&#x02009;histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood 112(7):2965&#x02013;2968<pub-id pub-id-type="pmid">18660380</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>KTE</given-names></name><name><surname>Tay</surname><given-names>AZE</given-names></name><name><surname>Kuick</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Algar</surname><given-names>E</given-names></name><name><surname>Taubenheim</surname><given-names>N</given-names></name><etal/></person-group><article-title>ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion</article-title><source>Mod Pathol</source><year>2019</year><volume>32</volume><issue>5</issue><fpage>598</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1038/s41379-018-0168-6</pub-id><pub-id pub-id-type="pmid">30573850</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Chang KTE, Tay AZE, Kuick CH, Chen H, Algar E, Taubenheim N et al (2019) ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion. Mod Pathol 32(5):598&#x02013;608<pub-id pub-id-type="pmid">30573850</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Kemps</surname><given-names>PG</given-names></name><name><surname>Picarsic</surname><given-names>J</given-names></name><name><surname>Durham</surname><given-names>BH</given-names></name><name><surname>Helias-Rodzewicz</surname><given-names>Z</given-names></name><name><surname>Hiemcke-Jiwa</surname><given-names>L</given-names></name><name><surname>van den Bos</surname><given-names>C</given-names></name><etal/></person-group><article-title>ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition</article-title><source>Blood</source><year>2022</year><volume>139</volume><issue>2</issue><fpage>256</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1182/blood.2021013338</pub-id><pub-id pub-id-type="pmid">34727172</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Kemps PG, Picarsic J, Durham BH, Helias-Rodzewicz Z, Hiemcke-Jiwa L, van den Bos C et al (2022) ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood 139(2):256&#x02013;280<pub-id pub-id-type="pmid">34727172</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>